Bausch + Lomb (BLCO) to Release Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 19th. Analysts expect Bausch + Lomb to post earnings of $0.23 per share and revenue of $1.26 billion for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Bausch + Lomb Stock Performance

Shares of BLCO stock traded down $0.20 on Friday, hitting $16.44. 341,072 shares of the stock traded hands, compared to its average volume of 721,173. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The company has a market capitalization of $5.79 billion, a PE ratio of -15.65, a PEG ratio of 2.13 and a beta of 0.46. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The company's fifty day moving average is $17.67 and its 200 day moving average is $18.15.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Stifel Nicolaus dropped their price target on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating on the stock in a research report on Wednesday, January 29th. Citigroup lowered Bausch + Lomb from a "buy" rating to a "neutral" rating and dropped their price target for the company from $24.00 to $22.00 in a research report on Wednesday, December 11th. Wells Fargo & Company dropped their target price on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Thursday, January 16th. Bank of America reaffirmed an "underperform" rating and issued a $18.00 target price on shares of Bausch + Lomb in a research report on Thursday, December 12th. Finally, Royal Bank of Canada dropped their target price on Bausch + Lomb from $23.00 to $22.00 and set an "outperform" rating on the stock in a research report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $20.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.